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In 2014, the National Research Council (NRC) published Review of EPA’s Integrated Risk Information System
(IRIS) Process that considers methods EPA uses for developing toxicity criteria for non-carcinogens. These
criteria are the Reference Dose (RfD) for oral exposure and Reference Concentration (RfC) for inhalation
exposure. The NRC Review suggested using Bayesian methods for application of uncertainty factors (UFs)
to adjust the point of departure dose or concentration to a level considered to be without adverse effects
for the human population. The NRC foresaw Bayesian methods would be potentially useful for combining
toxicity data from disparate sourcesdhigh throughput assays, animal testing, and observational epide-
miology. UFs represent ﬁve distinct areas for which both adjustment and consideration of uncertainty
may be needed. NRC suggested UFs could be represented as Bayesian prior distributions, illustrated the
use of a log-normal distribution to represent the composite UF, and combined this distribution with a
log-normal distribution representing uncertainty in the point of departure (POD) to reﬂect the overall
uncertainty. Here, we explore these suggestions and present a reﬁnement of the methodology suggested
by NRC that considers each individual UF as a distribution. From an examination of 24 evaluations from
EPA’s IRIS program, when individual UFs were represented using this approach, the geometric mean fold
change in the value of the RfD or RfC increased from 3 to over 30, depending on the number of individual
UFs used and the sophistication of the assessment. We present example calculations and recommen-
dations for implementing the reﬁned NRC methodology.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Uncertainty factors (UFs) were developed in the 1980s by U.S.
Environmental Protection Agency (USEPA) scientists based on
margins of safety for determining acceptable daily intakes (ADIs)
(Dourson and Stara, 1983; Barnes and Dourson, 1988; Dourson,
1993, 1996; Dourson et al., 1996). The development and use of
uncertainty factors comprise an attempt to address the lack of
speciﬁcity in margins of safety and are designed to address speciﬁc
areas of uncertainty, thus enabling the development of data-
derived values to replace default values of generally 10-fold
(Dourson et al., 1996). The goal for any toxicity guidance value. Simon).
r Inc. This is an open access articlesuch as the Reference Dose (RfD), Reference Concentration (RfC) or
Tolerable/Acceptable Daily Intake (TDI/ADI) is not only protection
of human health consistent with the societal consensus for such
protection but also avoidance of an overprotective level that could
conceivably lead to excessive regulation (Simon, 2011). This balance
notwithstanding, the needs of regulation are immediate and these
exigencies are the basis for the continued regulatory embrace of
default values for UFs and their use in the derivation of reference
values (RfVs).
The individual UFs used in EPA toxicity assessments address ﬁve
distinct areas of uncertainty. Historical publications by EPA staff in
the 1980s provide much of the basis for four of the UFs, excluding
UF-D, applied for database deﬁciencies (Dourson and Stara, 1983;
Barnes and Dourson, 1988; Dourson and DeRosa, 1991). Subse-
quent publications introduced the basis for this latter database
factor, generally the absence of evidence regarding developmentalunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Abbreviations
ADI Acceptable daily intake
BMD Benchmark dose
DDEF Data-derive extrapolation factor
NRC National Research Council
POD Point of departure
RfD Reference dose
RfC Reference concentration
RfV Reference value
PBPK physiologically-based pharmacokinetic
TDI/ADI Tolerable/Acceptable daily intake
UFs Uncertainty factors
UF/EF uncertainty/extrapolation factor
LOAEL: Lowest observed no adverse effect level
NOAEL No observed adverse effect level
UF-L: LOAEL-to-NOAEL uncertainty/extrapolation factor
UF-S Subchronic-to-chronic uncertainty/extrapolation
factor
UF-A interspecies uncertainty/extrapolation factor
UF-A-TD toxicodynamic component of the interspecies
uncertainty/extrapolation factor
UF-A-TK toxicokinetic component of the interspecies
uncertainty/extrapolation factor
UF-H intraspecies uncertainty/extrapolation factor
UF-H-TD toxicodynamic component of the intraspecies
uncertainty/extrapolation factor
UF-H-TK toxicokinetic component of the intraspecies
uncertainty/extrapolation factor
UF-D uncertainty/extrapolation factor for database
deﬁciencies
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Dourson, 1993). All ﬁve areas of uncertainty are discussed in USE-
PA’s Review of the Reference Dose and Reference Concentration Pro-
cesses (USEPA, 2002b). The purposes of the individual UFs were to
address these ﬁve areas of uncertainty and, according to this
document, were:
… (1) the variation in sensitivity among the members of the human
population (i.e., inter-individual variability); (2) the uncertainty in
extrapolating animal data to humans (i.e., interspecies uncer-
tainty); (3) the uncertainty in extrapolating from data obtained in
a study with less-than-lifetime exposure to lifetime exposure (i.e.,
extrapolating from subchronic to chronic exposure); (4) the un-
certainty in extrapolating from a LOAEL rather than from a NOAEL;
and (5) the uncertainty associated with extrapolation when the
database is incomplete. (USEPA, 2002b)
Before the publication of EPA’s 2002 document, any un-
certainties not explicitly addressed by the ﬁve different UFs had
been addressed by the use of a modifying factor (MF). However, the
EPA 2002 document recommended discontinuation of the use of
MFs (USEPA, 2002b). In IRIS assessments developed today, all ﬁve
individual UFs are multiplied together and the composite UF
applied to the point of departure (POD) by arithmetic division,
generally as the ﬁnal step in the RfV development process.
Over time, the understanding of UFs as individual factors rather
than their combination has continued to grow. Each individual UF
consists of an adjustment and the uncertainty associated with the
adjustment; here, we identify the central value of a UF distribution
as a measure of adjustment and the variance as a measure of un-
certainty. In many of the IRIS derivations considered here, EPA has
chosen the UFs for speciﬁc reasons. Even Lehman and Fitzhugh
(1954) recognized their composite 100-fold UF was intended to
deal with several distinct areas of uncertainty (Dourson and Stara,
1983). However, the encoding of distinct areas of uncertainty as
individual factors rather than as an overall or composite factor is an
important distinction and is not fully recognized in NRC (2014).
The use of an overall composite UF or “safety factor” masks the
compounding conservatism inherent in the use of several UFs set at
default values and each intended to provide a highly protective
toxicity value (Burmaster and Harris, 1993; Burmaster and
Anderson, 1994; Cullen, 1994; Simon, 2011; Tatum et al., 2015).
The compounded conservatism in the use of many high-end values
will yield an overestimate of risk and the actual risk is likely to bemuch lower or even non-existent. Indeed, a highly conservative
policy-based assessment seems at odds with principles of trans-
parency and the use of science as a basis for societal decision-
making (Dourson and Stara, 1983; Lewis et al., 1990).
Although we use the familiar abbreviation UF in this paper,
these factors are also called extrapolation or adjustment factors
and, ideally, their values, whether chemical-speciﬁc or default, will
be based upon actual data (e.g., WHO-IPCS, 2005, 2014; Chiu and
Slob, 2015; USEPA, 2014).
The conceptual basis of the application of UFs using the standard
deviations of Bayesian prior distributions is described in the recent
Review of EPA’s Integrated Risk Information System (IRIS) Process
from the National Research Council (NRC, 2014). Here we consider
the NRC methodology in terms of both the mean and variance of
these distributions, provide several illustrations of this application,
and explore ways that these methods could be applied currently to
the development of RfVs within the IRIS program or in other similar
hazard assessment programs in public and private sectors. The
World Health Organization International Programme on Chemical
Safety (WHO-IPCS) recently released the Guidance Document on
Evaluating and Expressing Uncertainty in Hazard Characterization
that also endorsed probabilistic approaches; the methods and
practices described here are consistent with both the NRC report
and theWHO guidance (WHO-IPCS, 2014; Chiu and Slob, 2015). We
also provide a brief narrative on the considerations and best prac-
tices for the use of Bayesian methods for development of quanti-
tative uncertainty estimates in RfVs that could be put into practice
immediately.1.1. Chemical-speciﬁc adjustment factors and data-derived
uncertainty factors
In 2005, the WHO-IPCS released Chemical-Speciﬁc Adjustment
Factors for Interspecies Differences and Human Variability: Guidance
Document for Use of Data in Dose/Concentration Assessment (WHO-
IPCS, 2005). In this guidance, UFs are called chemical-speciﬁc
adjustment factors (CSAFs). Over a decade in development, this
document was introduced to provide methods for the incorpora-
tion of quantitative data on toxicokinetics or toxicodynamics into
the development of RfV/TDI values by modifying the default value
of 10 for each CSAF. Since 1994, Health Canada has been using a
data-derived procedure based on the developing WHO-IPCS
guidelines (Meek et al., 1994). In 2014, the U.S. Environmental
Protection Agency issued a similar document, Guidance for Applying
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Interspecies and Intraspecies Extrapolation (USEPA, 2014).
1.2. Bayesian and probabilistic approaches to UFs
In Review of EPA’s Integrated Risk Information System (IRIS) Pro-
cess (Chapter 7), the NRC outlines a Bayes approach to integrating
UFs in deriving toxicity values as well as integrating several studies
or data from diverse sources (NRC, 2014). The NRC’s approach as-
sumes that the uncertainty in the estimated point of departure (e.g.,
benchmark dose) as well as that encoded by the UFs can be char-
acterized using appropriately speciﬁed distributions and uses the
log-normal distribution for illustration. NRC (2014) was explicit in
promoting systematic approaches to incorporating quantitative
uncertainties into toxicity value development and foresaw that
toxicity value development would likely rely on a range of disparate
data sources, including high throughput in vitro assays, animal
testing, and/or epidemiological studies.
The general approach as described in the NRC report differs
from the classic UF approach in two aspects: ﬁrst, uncertainty from
a speciﬁc source can be characterized with greater ﬂexibility and
representativeness as a distribution or range of values rather than
as a point estimate; and, second, the use of a distribution provides a
system that can accommodate a variety of types of data to reﬁne
existing toxicity factors. In the past, a number of authors have
characterized UFs using the log-normal distribution, likely because
of its mathematical tractability (Price et al., 1997; Swartout et al.,
1998; Gaylor and Kodell, 2000).
Perhaps more important, any distribution can be characterized
by parameters that specify the location and scaledfor the log-
normal distribution, these would be the natural logarithms of the
geometric mean and geometric standard deviation, here symbol-
ized as m and s respectively. Because UFs are intended to address
both a location adjustment and the attendant uncertainty, both the
location and scale of the UF need to be speciﬁed. For those UFs not
needing an adjustment, the location will be zero (i.e. geometric
mean ¼ 1 or m ¼ 0 for a log-normal distribution) indicating the
factor addresses uncertainty only. For other UFs, such as UF-L and
UF-S, the extrapolation from a LOAEL to a NOAEL will require some
degree of numerical adjustment as well as an expression of un-
certainty and the same idea will hold true when extrapolating from
a sub-chronic to chronic duration from animal bioassay data. This
idea of adjustment and uncertainty will be discussed throughout
the rest of this paper.
1.3. Historical context for the NRC IRIS review
Formaldehyde became a high priority public health issue after
its discovery in FEMA trailers sent to the Gulf Coast as shelters for
Hurricane Katrina victims (Jacobs, 2011). Hence, EPA requested that
the NRC review the draft IRIS assessment for formaldehyde; the
resulting review was highly critical of the process used, pointing
out the assessment both lacked transparency and consistency and
did not provide sufﬁcient documentation of methods or the char-
acterization of uncertainty and variability (NRC, 2011, p. 26). The
ﬁnal chapter of the NRC review (Chapter 7) provided a general
critique of the IRIS process and suggestions for revising that process
(NRC, 2011).
Following the NRC formaldehyde review, the U.S. Congress held
several hearings to examine EPA’s IRIS program and to address
concerns raised regarding EPA’s overall IRIS process. The result was
that the U.S. Congress requested that NRC assess the existing and
planned changes in IRIS, and in 2014, NRC released their review.
NRC’s forward-looking approach sought to provide a framework
for the inclusion of data from multiple sources such as highthroughput in vitro assays, animal testing and epidemiological ob-
servations in humans. Such an approach would easily accommo-
date newer types of data to reﬁne existing RfVs. However, what is
missing from the NRC report is a discussion of ways to implement
these new methods into current IRIS assessmentsdhence, a pri-
mary purpose of this paper is to provide such a discussion with
examples as a proof of concept and suggestions for best practices
when implementing these methods.
1.4. The critical effectdthe basis of the reference value
To understand how NRC’s suggestions differ from EPA’s current
practice, this section provides a brief discussion of the concept of
the critical effect as the most appropriate biological basis of the RfV.
EPA deﬁnes the critical effect as “the ﬁrst adverse effect or its
known precursor, that occurs in the most sensitive species as the
dose rate of an agent increases” (USEPA, 2011). The critical effect is
one effect in a spectrum of biological changes from adaptive re-
sponses to frank effects.
At low doses, biological responses occur in a continuum and are
most often adaptive responses. These adaptive responses enhance
the organism’s ability to withstand a challenge. As dose increases,
compensatory effects occur, enabling the organism to maintain
overall function with neither further enhancement of these effects
nor signiﬁcant harm. As dose increases further, the critical effect
and/or downstream adverse effects occur as functional impair-
ments or pathologic lesions that incur signiﬁcant cost or harm. At
some point these adverse effects become irreversible and overtly
manifest as disease (Patlewicz et al., 2013).
Generally, the current practice in EPA’s IRIS program is to select
a single critical study and single critical effect upon which to base
the point of departure (POD) for an RfV value. In contrast, NRC
(2014) suggested that a meta-analytic approach be used to
combine the results of multiple studies. NRC (2014) also provided a
few examples of combining studies using such meta-analytic ap-
proaches and the application of UFs using Bayesian methods. Cat-
egorical regression can also be used to combine results of multiple
studies, including studies of effects of different severities with
methods developed by EPA (Hertzberg and Dourson,1993; Dourson
et al., 1997; Teuschler et al., 1999).
2. Uncertainty factors as distributions
Historically, the general assumption within the risk assessment
community has been that UFs could be represented by a range of
generally up to 10-fold (Felter and Dourson, 1998) Although the
understanding of the biology underlying the choices of UF values
has grown, some imprecision remains (e.g., WHO-IPCS, 2014; Chiu
and Slob, 2015; Bokkers and Slob, 2007). Most ranges can be
characterized as probability distributions and an uncertainty factor
can be assumed to follow a distribution with a speciﬁc range of
variation. Here, as does NRC (2014), we also characterize the dis-
tribution of an uncertainty factor as log-normal with the underly-
ing normal distribution on a natural log scale with a mean denoted
by m and a standard deviation denoted by s.
For example, Swartout et al. (1998) suggested a 3-parameter
log-normal as a “reference” UF distribution with a 50th percentile
of 3.16, a 95th percentile of 10 and a lower limit or offset parameter,
t ¼ 1. For such a distribution, all adjustments will be greater than
one. These authors give the base ten logarithms of the offset-
adjusted median, i.e., log10 (median e offset), with a value of
0.335 and the standard deviation with a value of 0.377. Using nat-
ural logarithms, the corresponding values would be m ¼ 0.770 and
s ¼ 0.867 and following a selection of a value using these param-
eters, one would also need to exponentiate the selected value and
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Attempts have been made to determine the range of human
variability and thus “groundtruth” the intraspecies UF (Dourson
et al., 1996; Renwick and Lazarus, 1998). Both EPA’s recent guid-
ance on data-derived extrapolation factors (DDEFs) and the WHO-
IPCS guidance on CSAFs are silent on the nature of the distribution,
although the WHO document mentions log-normal distributions
(WHO-IPCS, 2005; USEPA, 2014).
Swartout et al. (1998) likely chose the log-normal distribution
more for computational tractability and ﬂexibility rather than for
the ﬁdelity with which this distribution represents quantitative
adjustment and uncertainty. This point is examined further else-
where in this paper.
When NOAELs or LOAELs are used as PODs, their value is
unavoidably skewed by study design and we recognize that the
BMD as a point estimate of the POD is also imprecise. Toxicological
responses follow the laws of thermodynamics and logarithms are
the most appropriate expression of dose (Clark, 1933; Bruhn et al.,
2003; Waddell, 2008, 2010; Hughes and Aronson, 2010). When the
sample size of the underlying study is sufﬁciently large, by the
central limit theorem, the maximum likelihood estimator of the
POD will approximate a normal distribution; this normal approxi-
mation is also the case for this estimator of the POD on a loga-
rithmic scale. Further, the use of lognormal distributions would be
more robust against variation skewed toward the heavy right tail
when the sample size is small to moderate. Zhu et al. (2007) con-
ducted an extensive bootstrap simulation of four developmental
studies that represent the typical dose-response shapes observed
in generation II developmental studies conducted by NTP. The
distributions of the BMD distributions at BMR levels of both 1% and
5% BMR level are negatively skewed to a considerable extent
(Table IV in Zhu et al., 2007). Hence, using normal distributions of
the BMD is not advisable in practice because substantial bias would
occur in estimating BMDLs (Zhu et al., 2007; USEPA, 2012a).
These explanations notwithstanding, the true form of the dis-
tribution of the BMD remains unknown and is likely case-speciﬁc.
Hence, similar to the NRC and others in the history of RfV devel-
opment, we acknowledge this imprecision and also chose to
represent both the POD and the UFs with log-normal distributions
for illustration.
2.1. Adjustment vs. accounting for uncertainty
UFs, as traditionally applied, seek to provide a “reasonable
maximum adjustment” both for the necessary extrapolations and
for developing a protective value in the face of uncertainty
(Dourson and Stara, 1983; Barnes and Dourson, 1988). Hence, any
choice of the form of the distribution of uncertainty needs to
consider both adjustment and uncertainty. The central value of the
distribution is a reasonable choice for numerical adjustment
whereas the variance is likely a representation of uncertainty. The
central values will be different for different UFs and will affect the
choice of a value for the variance to provide adequate coverage.
For example, even if the value of a NOAEL cannot be established
from a study, by deﬁnition, the value will be less than the measured
LOAEL. Hence, the central value of any distribution representing the
LOAEL-to-NOAEL UF (UF-L) will be greater than unity and will
constitute an adjustment and the variance will be an estimate of
the attendant uncertainty.
As noted, a chronic point of departure will be lower than a
subchronic POD, and similar to the case of UF-L, the central value of
UF-S represents the central value of this adjustment for dosing
duration and the variance represents the surrounding uncertainty.
The factors for animal-to-human extrapolation (UF-A) and hu-
man variability (UF-H), even when split into toxicokinetic andtoxicodynamic components, also contain both elements of adjust-
ment and uncertainty (e.g., Table 2).
Even the factor for database deﬁciencies assumes that missing
toxicity data will necessarily represent an endpoint that, if tested,
would result in a lower RfV. The database for a given chemical may
not include testing for developmental and reproductive toxicity
(DART) and adjustment is deemed necessary because of concern for
this type of endpoint (Dourson et al., 1992, 1996; USEPA, 2002b;
Blackburn et al., 2015).
2.2. Sources of uncertainty represented by the ﬁve uncertainty
factors
As previously mentioned, ﬁve distinct areas of uncertainty are
addressed by the UFs used in EPA assessments. Separating these
ﬁve types of uncertainty was not addressed in NRC (2014). The use
of UFs for human variability and interspecies extrapolation was
developed fromwork in the 1950s of Lehmann and Fitzhugh of the
Food and Drug Administration as well as others (Lehman and
Fitzhugh, 1954). At that time, a 100-fold UF was proposed to ac-
count for interspecies differences and human variability with the
latter including allowance for sensitive subpopulations and, to a
lesser extent, possible synergistic effects with other chemicals. Data
regarding inter- and intra-species differences were considered and
the likely intent was that eventually a data-derived probabilistic
method would be used in lieu of the 100-fold default. In 1980, EPA
recommended an additional UF between 1 and 10 in cases when an
ADI value was estimated from a LOAEL rather than a NOAEL
(Dourson and Stara, 1983).
Renwick and Lazarus (1998) provide historical details of the
separation of the inter- and intraspecies UFs into toxicokinetic and
toxicodynamic components. WHO-IPCS (2005) indicates the
default interspecies UF should be split into factors of 2.5 and 4 for
toxicodynamics and toxicokinetics respectively whereas the intra-
species UF should be split evenly into default components of √10
(i.e., 3.16). USEPA (2014) suggests that both default inter- and
intraspecies factors can be split evenly as√10. Generally, this value
is rounded to 3. In addition, when supporting data exist, EPA (2014)
indicates that both the toxicokinetic and toxicodynamic compo-
nents of the interspecies UF can have a value of less than one
(USEPA, 2014).
Using the traditional method for UF application by dividing into
the POD, when uncertainties are identiﬁed from distinct sources,
individual UFs should be speciﬁed and generally applied at the
appropriate stage of RfV development to ensure the transparency
and speciﬁcity of the process (e.g., Simon et al., 2008, 2009). Using
only a composite UF applied at the end of the process diminishes
this transparency. Generally, this same principle should be applied
when using Bayesian methods to individual UFs singly and at
different stages within the RfV process, based on the nature of the
adjustment as shown in Fig. 1. The issue of when to apply particular
individual UFs will be examined further in the DISCUSSION.
The choice of numerical values for m and s for log-normal UF
distributions allows one to decide both the degree of adjustment
and uncertainty and whether to remain consistent with default
uncertainty values or to choose a different valuedby specifying the
percentile corresponding to the degree of uncertainty. Table 1
provides a range of UF values for a generic log-normal UF distri-
bution; the value of m is zero and the table shows the values of the
Bayesian prior standard deviations on a natural log scale for a range
of percentiles corresponding to one-sided conﬁdence intervals. The
table is similar to Table 7-2 in NRC (2014). The highest UF value in
the NRC table is 1000 whereas the highest UF value shown in
Table 1 is 10dthe reason is that we believe these methods should
be applied to individual UFs/EFs rather than to the composite UF,
Table 1
Standard deviations of the log-normal distributions used for application of individual uncertainty/adjustment/extrapolation factors with geometric means of one, UF-A and
UF-H. The value of m is set equal to zero, under the assumption that no adjustments are needed. Hence, these UF values will be applicable to UF-A and UF-H.
Value of UF 20th percentile
or 80th percentile
10th percentile
or 90th percentile
5th percentile
or 95th percentile
2.5th percentile
or 97.5th percentile
0.5th percentile
or 99.5th percentile
Z-score 0.842 1.282 1.645 1.960 2.576
Standard deviation values for UFs > 1 below are added when combined
2 0.823 0.541 0.421 0.354 0.269
2.5 1.089 0.715 0.557 0.468 0.356
3 1.305 0.857 0.668 0.561 0.427
3.16 1.367 0.898 0.699 0.587 0.447
10 2.736 1.797 1.400 1.175 0.894
Percentile of the left tail (e.g. 5-percentile) applies to UF < 1; percentile of the right applies to UF > 1.
Conﬁdence level is equal to (100 e left) percentile for one-sided values and (100e2  left percentile) for two-sided values.
The actual UF value corresponds to exp(Z-score * Table Value); hence, for a UF of 10 corresponding to the 95th percentile, UF ¼ exp(0 þ 1.645*1.4) ¼ 10.
Table 2
Means and Standard Deviations of log-normal distributions used for UF-Awhen humans are known to be less sensitive than animals. To use these UFs, the value of mwould be
added to the POD and the value of s combined with the other UFs as shown in Eq. (1b). A value of m ¼ ln (0.3) assumes that humans are known to be about 1/3 as sensitive as
animals. The value of the standard deviation are used to obtain a UF value equivalent to that shown in the leftmost column. Hence, the data might show humans are 1/3 as
sensitive but to account for uncertainty, humans and animals are considered equally sensitive. In the bottom two rows, humans are known to be 1/10 as sensitive as animals
and to account for uncertainty, humans are considered either 1/3 as sensitive or equally sensitive (Value of UF ¼ 0.3 or 1 respectively).
Value of UF 20th percentile
or 80th percentile
10th percentile
or 90th percentile
5th percentile
or 95th percentile
2.5th percentile
or 97.5th percentile
0.5th percentile
or 99.5th percentile
Z-score 0.842 1.282 1.645 1.960 2.576
Standard deviation values for UFs < 1 are subtracted when combined, assuming m ¼ ln (0.3)
1 1.431 0.939 0.732 0.614 0.467
Standard deviation values for UFs < 1 are subtracted when combined, assuming m ¼ ln (0.1)
0.3 1.306 0.858 0.669 0.561 0.428
1 2.736 1.797 1.400 1.175 0.894
Fig. 1. Scheme for application of UFs at the appropriate stage of the RfD process. Following BMD modeling in animals, the internal dose metric may be adjusted for with UF-L and
UF-S. The animal dose metric at the POD is adjusted with the UF-A-TD to obtain the human internal dose metric at the POD. This human POD is adjusted with the UF-H-TK to obtain
the POD in sensitive humans. The human PBPK model is used to obtain external doses and the UF-D is applied if necessary.
T.W. Simon et al. / Regulatory Toxicology and Pharmacology 80 (2016) 9e24 13the product of individual UFs. In addition, the use of a distribution
for UFs necessitates the choice of both m and s. Both parametersaffect coverage, an important consideration for the protectiveness
of the UF value chosen.
T.W. Simon et al. / Regulatory Toxicology and Pharmacology 80 (2016) 9e2414The traditional method for application of UFs involves division
of the POD by the UFs and division is equivalent to subtraction of
logarithms. The use of UFs less than onewill mean that these values
will be added to the logarithm of the POD rather than subtracted
and thus will increase the value of the RfV.
When values of UF-A less than unity are used, this choice in-
dicates that humans are measurably less sensitive than the animal
test species (e.g., Simon et al., 2008, 2009). USEPA (2014) indicates
that the extrapolation factor may be less than one for both the
toxicokinetic and toxicodynamic components of the interspecies
extrapolation factor when supporting data exist. In such a case, one
would base the value of such a data-derived UF on measured dif-
ferences between humans and the test species. The central value,
i.e., the mean or median, of these measured differences would
inform the adjustment value or m and the spread of the differences
would inform s, the measure of uncertainty. Use of an interspecies
UFwith a value less than unity would, of course, depend on the data
in humans and the test species; here, for illustration, Table 2 shows
values of m less than one that represent a reduction of the margin of
safety as an adjustment to be added directly to the natural loga-
rithm of the POD and the value of s would be combined using Eq.
(1b) below to increase the margin of safety, thus accounting for
uncertainty.
In general, an UF/EF from a given source is considered to be both
a numerical adjustment with a conservative upper bound of un-
certainty. The Bayes approach described here accounts for both the
adjustment and the uncertainty. A point estimate may be selected
from this distribution or the entire distribution may be used. We
emphasize that the mean value is the central value of the adjust-
ment and standard deviation characterizes the range of uncertainty
inherent in this adjustment. Hence, risk analysts will need the
ﬂexibility to choose different means and standard deviations and
different percentiles and, thus, different conﬁdence levels for a
given UF, and will also need to provide a rationale for their choices.
The increased ﬂexibility and the need for a rationale will increase
the transparency and the likely utility of any RfV.
2.3. Use of UF distributions to represent a percentile of the target
population included in an RfV value
Science and Decisions: Advancing Risk Assessment, from the NRC
in 2009 distinguished between adverse effects occurring on the
individual level characterized by severity or magnitude, and
adverse effects of a particular magnitude occurring on a population
level characterized by their incidence or frequency within the
population (NRC, 2009).
This idea of protecting the population at a given risk or inci-
dence level for a particular effect magnitude was ﬁrst advanced as
part of a “Straw Man” proposal to deﬁne the RfV in a more quan-
titative fashion (Hertzberg and Dourson, 1993; Dourson et al., 1997;
Teuschler et al., 1999; Hattis et al., 2002).
This paper is a proof-of-concept and a ﬁrst attempt to learnwhat
aspects of Bayesian methods for UF application can be used either
immediately or in the near term. Hence, consistent with current
EPA practice, distinguishing magnitude and incidence was not
implemented here.
3. Methods
The derivation of RfD and RfC values followed generally the
suggestions of NRC (2014). We considered each individual UF,
rather than the composite UF, to be represented by a Bayesian prior
distribution characterized by its mean and variance. These indi-
vidual distributions can be combined to obtain a measure of the
overall adjustment and attendant uncertainty. Hence, the methodshown here represents a methodological reﬁnement of the one
used in the phenol example on page 121 of Chapter 7 of NRC (2014).
Practically, we believe that individual UFs represent areas of
uncertainty too dissimilar to support the use of a single distribution
for the composite UF obtained as the product of individual UFs in a
Bayesian framework. The use of a composite UF would ignore the
knowledge of uncertainty from speciﬁc sources, consistent with the
original rationale for the ﬁve UFs. For example, the extrapolation of
experimental animal toxicokinetics to human toxicokinetics (i.e.,
the UF-A-TK) is not the same as the extrapolation of a NOAEL or
BMDL from a subchronic experimental animal study to its chronic
equivalent (i.e., the UF-S); speciﬁc knowledge about the uncer-
tainty in interspecies differences in toxicokinetics and chronic vs.
subchronic exposure will likely warrant choosing different adjust-
ments and different ranges of uncertainty. Hence, we believe the
best practice is to assume that each factor is independent and then
to choose distributions that represent each individual UF and apply
these at the appropriate stage during the development of an RfD or
RfC, as in Fig. 1.
Eq. (1a) below shows the combination of a single distribution for
the composite uncertainty factor with the uncertainty in the POD,
as in the phenol example in NRC (2014). Eq. (1b) shows the
reﬁnement of this method recommended here for combining the
distributions representing both adjustment and uncertainty for
each individual UF with the uncertainty in the POD.
lnðPODÞ  Za
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2POD þ s2UFcomp
q
(1a)
lnðPODÞ

X
mUFZa
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2POD þ s2UFS þ s2UFL þ s2UFA þ s2UFH þ s2UFD
q
(1b)
Eq. (1b) implies that for each UF both parameters m and s are
known: 1) the central value characterized by the mean and 2) the
range characterized by the variance. In contrast, Eq. (1a) implies
that only the range of total uncertainty from all sources aside from
that in the POD is known and that the adjustment or mean is
assumed to be zero. For any of the UF distributions, the value of m
may be zero, indicating no adjustment, or a positive or negative
value, and in Eq. (1b), the sum of the adjustments is shown as Sm. In
contrast, in Eq. (1a), whether an adjustment is associated with this
total uncertainty and just how much of this total variation is
attributable to each source of uncertainty remains unspeciﬁed.
Thus, the relative magnitude of any area of uncertainty will also be
unspeciﬁed and any dominant uncertainty cannot be identiﬁed. As
noted in the legend to Table 2 and above, the values of m for UF-A
may be less than zero; in such cases, the absolute values of the
logarithms of their values will be added to and not subtracted from
the POD.
The ﬁve examples below serve to suggest initial ways to use the
methods described in NRC (2014) in the immediate term. Save for
example 2 below, the value of m is assumed to be zero for all UFs,
consistent with NRC (2014). This assumptionwas maintained in the
calculation of RfVs for 24 recent IRIS assessments presented below
in order to facilitate comparison with the IRIS values. As discussed,
this assumption about the value of m for all UFs is clearly incorrect,
but with this assumption, the results can be meaningfully
compared with the method from NRC (2014) as shown in Eq. (1a)
and with those in EPA’s IRIS database. These examples are by no
means deﬁnitive; however they do provide a ﬁrst look at replacing
default single point estimates for UFs with distributions, and, thus,
provide an improvement that has been recommended in multiple
NRC reports (NRC, 2006, 2007b, 2009, 2014).
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In this example, the general method is illustrated. The BMDL
represents the lower 95% one-sided conﬁdence limit on the BMD,
consistent with USEPA (2012a). Note that in practice, a different
level of conﬁdencemay be chosen and one can specify this choice in
EPA’s Benchmark Dose Software. From the BMD modeling con-
ducted by EPA for phenol, the values of the BMD and BMDL were
157 mg/kg/d and 93 mg/kg/d respectively (USEPA, 2002b). The
absolute value of the Z-score associated the BMDL is 1.645, indi-
cating the BMDL occurs at the lower 95% one-sided conﬁdence limit
of the BMD or the 5th percentile of the distribution of uncertainty
in the BMD. Assuming ln (BMD) follows a normal distribution with
the mean ¼ ln (157) and the lower 95% one-sided conﬁdence level
or 5th percentile ¼ ln (93), the standard deviation, s, of the dis-
tribution of uncertainty in the POD is given by:
lnð157Þ  lnð93Þ
1:645
¼ 0:318 (2)
where the symbol “ln(x)” indicates the natural logarithm of the
value of “x”.
In deriving the RfD for phenol, EPA used three individual UFs,
(BMDL/(UF-A  UF-H  UF-D)); these were interspecies UF-A with
a default value of 10, intraspecies UF-H with a default value of 10
and a database uncertainty factor, UF-D, with a value of 3. USEPA
(2002a) provides a rationale for the choice of the default values
for UF-A and UF-H and indicates the reduced value of UF-D is based
on the relatively complete database; however, the value of UF-D
was chosen to be greater than unity because only a single short-
term study indicating the potential for hematological effects was
available.
Here we assume each UF can be characterized by a log-normal
distribution with mean m representing any needed adjustment
and a standard deviation s representing the attendant uncertainty.
When m ¼ 0, s is calculated as ln (UF)/Z-score (for the 95th
percentile, this would be ln (UF)/1.645). The overall uncertainty in
the RfD also follows a log-normal distribution that combines into
its overall standard deviation the variation/uncertainty in the POD
with the adjustments all equal to zero (not shown explicitly in Eq.
(3a)) and uncertainty at the 95th percentile of the log-normal
distributions of the inter- and intraspecies UFs having each a
value of 10 and the database uncertainty factor having a value of 3.
Table 1 provides the values of s for the UFs for a range of percen-
tiles/conﬁdence limits (Eq. (3a)). The RfD on the log-scale is taken
as the 5th percentile of this distribution, i.e. 1.579.
lnð157Þ  1:645*
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:3182 þ 1:42 þ 1:42 þ 0:6682
p
¼ 1:579
(3a)
RfD ¼ e1:579 ¼ 4:85x5 mg=kg=d (3b)
An RfV is expressed with one or at most two decimals (Eq. (3b))
(USEPA, 1989). For comparison, the RfD value for phenol from EPA’s
IRIS database is 93 mg/kg/d divided by 300 or 0.3 mg/kg/d. The RfD
value for phenol presented in NRC (2014) was derived using Eq. (1a)
above and assuming the BMDL was the one-sided lower 97.5th
percentile of the uncertainty in the BMD and that the composite UF
represented the 97.5th percentile of the total uncertainty; this
value was 0.5 mg/kg/d.
The reduction of total value of uncertainty that occurs by
dividing the total uncertainty into components is a general phe-
nomenon, not speciﬁc to RfV development; the standard deviation
for the composite UF would be the sum of the standard deviations
as follows:scomposite¼
lnðUF1 xUF2 xUF3 x ::: xUFkÞðm1þm2þm3þ ::: þmkÞ
Za
¼s1þs2þs3þ ::: þsk
(4)
The variance for the composite UF would be:
s2composite ¼ ðs1 þ s2 þ s3 þ ::: þ skÞ2 (5)
In contrast, when individual UFs are combined within the
Bayesian framework described in NRC (2014), the overall variance
would be sum of the individual variances as follows:
s2 ¼ s21 þ s22 þ s23 þ ::: þ s2k (6)
Thus the variance for the composite UF will be far greater than
the variance when an independent distribution is assumed for each
component UF.
To demonstrate this point, we will consider the combination of
three UFs, each with a default value of 10 representing 95%
coverage. On a natural log scale, the distributions would have m ¼ 0
and s ¼ 1.4 (Table 1). The composite UF would be 1000, scomposite
on a natural log scale would be 4.2, and the variance would be 17.6.
When the UFs are combined as in Eq. (6), the overall standard
deviation would be 2.4 and the variance would be 5.9. Intuitively,
the value of the composite UF has a 5% chance to be beyond the
overall 95th percentile whereas the chance of being above 95th
percentile for all individual UFs simultaneously is (0.05)^ k, much
smaller than 0.05. Hence, this use of a composite UF is another
example of compounding conservatism (Burmaster and Lehr, 1991;
Burmaster and Harris, 1993; Von Stackelberg and Burmaster, 1993;
Cullen, 1994; Simon, 2011; Tatum et al., 2015).
This simple example of the reﬁned method (Eq. (1b)) demon-
strates not only the combination and application of individual UFs
using Bayesian methods but also the ﬂexibility and potential of the
use of informed choices for the values of the mean adjustment, the
standard deviation and percentile that each individual UF repre-
sents. In addition, the Bayesian framework provides the ability to
develop sequential updates to an RfD/RfC as new knowledge about
these uncertainties becomes available.
3.2. Example 2: adjusting the POD and accounting for uncertainty
We wished to provide an example of an adjustment to the POD
for UF-L that implies a non-zero adjustment and we chose the RfC
for 1,4-dioxane. In the IRIS derivation, the composite UF was 1000,
consisting of UF-A¼ 3, UF-H¼ 10, UF-L¼ 10 and UF-D¼ 3. The POD
was a NOAEL based on the critical effect of sclerosis of the lamina
propria, and a LOAEL for the critical effects of atrophy and respi-
ratory metaplasia of the olfactory epithelium. The value of the POD
was 32.2 mg/m3 and was considered a LOAEL (USEPA, 2013b).
The values of m for UF-A, UF-H and UF-D were assumed to be
zero. The values for m and s for UF-L were obtained from Table 3 of
Pieters et al. (1998). The geometric mean and geometric standard
deviation of the LOAEL/NOAEL ratio values from 175 chronic studies
are reported as 4.5 and 1.7 respectively. These values are equivalent
to m ¼ 1.504 and s ¼ 0.531.
Hence, the value of the RfC is calculated as:
lnð32:2Þ  1:504 1:645*
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:6682 þ 1:4002 þ 0:5312 þ 0:6682
p
¼ 0:940
(7a)
RfC ¼ e0:940 ¼ 0:39y0:4 mg=m3 (7b)
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adjustment and the value from Table 1 for UF-L¼ 10, i.e. m¼ 0 for all
UFs, including UF-L.
lnð32:2Þ  1:645*
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:6682 þ 1:4002 þ 1:4002 þ 0:6682
p
¼ 0:137 (7c)
RfC ¼ e0:137 ¼ 0:87y0:9 mg=m3 (7d)
In this instance, the adjustment with a value of ln (4.5) for the
use of a LOAEL along with the measured variance in a dataset of 175
LOAEL/NOAEL ratios led to a more protective toxicity factor than
using m ¼ 0 (Table 3 and Eq. (7)).
A full exploration of the issues of adjustment and coverage is
beyond the scope of this paper; nonetheless, we wanted to provide
an example calculation as a gateway to future work. The point of
this example is that both the choices of both themean and standard
deviation of the log-normal distribution chosen to represent a
particular UF affect the amount of adjustment and the degree of
coverage.3.3. Example 3: methanol RfCdincorporation of physiologically-
based pharmacokinetic (PBPK) modeling for interspecies
extrapolation
In this example, we illustrate the stages at which the various UFs
are applied, as shown in the scheme in Fig. 1. This example will be
revisited in the DISCUSSION. EPA selected decreased brain weight
in rats as the critical effect and used a PBPK model to obtain the
POD as an area-under-the-curve (AUC) in rat dams in units of mg-
hr/L (USEPA, 2013a). A decrement of one standard deviation from
the control mean was used as the benchmark response (BMR). The
Hill model was chosen and a BMD1SD of 1730 mg-hr/L and a
BMDL1SD of 858 mg-hr/L were obtained. Assuming the BMDL1SD
is the 95% lower one-sided conﬁdence level or 5th percentile, the
standard deviation of the distribution of uncertainty in the animal
POD is
lnð1730Þ  lnð858Þ
1:645
¼ 0:426 (8)
The value of the interspecies factor or UF-A used by EPA was 3,
reduced from 10 because a PBPKmodel was used to extrapolate the
toxicokinetic component. This choice represents the 95% one-side
conﬁdence limit of uncertainty associated with the toxicody-
namic component of interspecies extrapolation; further, this choice
assumes that humans could be at most slightly more than three-
fold more sensitive than the test species in terms of toxicody-
namics and that the value of 3 as a high percentile represents a
conservative choice. An estimate of the actual value representing
interspecies toxicodynamic differences is not available; if so, the
value of this estimate would be used as the value of m of UF-A-TD
instead of assuming m ¼ 0. The human POD as the AUC derived
from the animal AUC BMD1SD would be
lnð1730Þ  1:645*
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:4262 þ 0:6682
p
¼ 6:152
expð6:152Þ ¼ 470 mg hr=L (9)
To obtain the human-equivalent concentration (HEC) in ppm,
EPA (2013) provided a single equation that represented the human
PBPK model and is shown below for completeness:
HECðppmÞ ¼ 0:02308*AUC þ 1734*AUC
1098þ AUC (10)
Using Eq. (10), the HEC corresponding to 470 mg-hr/L is531 ppm. USEPA indicates that the PBPK model captured in Eq. (10)
is valid only for HEC values below 500 ppm. Nonetheless, themodel
was used at this stage to remain faithful to the scheme shown in
Fig. 1. Additional information on the derivation of the Methanol RfC
indicates that the most accurate range of Eq. (10) is between 500
and 1000 ppm; this information is provided in Supplementary
Content.
EPA chose a value of 10 for the combination of the toxicody-
namic and toxicokinetic components of the intraspecies UF-H ac-
counting for lack of knowledge of true human variability and
assuming that the value of 10 represents the “best guess” of the 95%
one-sided conﬁdence limit of human variability (WHO-IPCS, 2014).
UF-H is best applied to the human-equivalent concentration ob-
tained from Eq. (10) representing the result of applying human
PBPK model. Because of the lack of data on reproductive, devel-
opmental and chronic effects in non-human primates, EPA chose to
use a database deﬁciency UF-D with a value of 3. The choice of this
value indicates that should a full database become available, one
could be 95% certain that the value of the RfC would be reduced by
no more than three-fold. The values of both UF-H and UF-D rep-
resented the 95% one-sided conﬁdence limits (Table 1) were
applied to the HEC of 531 ppm as follows:
lnð531Þ  1:645*
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1:42 þ 0:6682
p
¼ 3:721 (11a)
RfC ¼ e3:721 ¼ 41:3 ppm ¼ 54 mg
.
m3y50 mg
.
m3 (11b)
For comparison, this value is 2.5 fold greater than the RfC for
methanol in IRIS of 20 mg/m3.3.4. Example 4dcombining PODs from multiple studies-PCE
In this example, Bayesian updating is shown for the accommo-
dation of different data sets. The advantage of this method is a
reduction in uncertainty in the POD. For perchlorethylene, EPA
considered two separate studies as sources for POD values; both
studiesmeasuredmean exposure of dry cleaningworkers (Cavalleri
et al., 1994; Echeverria et al., 1995). These two studies observed
changes in vision in dry cleaning workers and the exposure con-
centrations are thus considered LOAELs (USEPA, 2012b).
Cavalleri et al. (1994) provide the arithmetic mean and arith-
metic standard deviation of 6.23 ± 6.66 ppm as the concentrations
to which 35 dry cleaning workers were exposed as a time-weighted
average, equivalent to 42 ± 45 mg/m3. This exposure was duration-
adjusted to represent constant exposure as follows:
ð42±45Þmg
.
m3 x
5d
7d
x
10m3d
20m3d ¼ ð15±16Þmg
.
m3 (12)
The air concentrations of PCE were measured with personal
passive samplers. The range of values is from 0.38 to 31.19 ppm. The
original data are not available, but the coefﬁcient of variation of
these air concentrations is 6.66/6.23, over 100%, and the concen-
tration range is about 100 fold. Thesewide variations are suggestive
of a heavy right-tailed distribution consistent with the character-
istic shape of a log-normal distribution. The geometric mean of
10.3 mg/m3 and geometric standard deviation of 2.391 were
calculated from the arithmetic mean and arithmetic standard de-
viation (Limpert et al., 2001).
With such a wide range of exposure, considerable uncertainty
exists in the interpretation of the mean value as an effect level.
Within the approximately 100-fold range of exposure, some frac-
tion of those exposed were sufﬁciently sensitive to experience vi-
sual changes; however, the unknown variations in both exposure
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effect, and the contributions of these two factors cannot be sepa-
rated. This compounded uncertainty of exposure and sensitivity
notwithstanding, the standard error of the duration-adjusted
arithmetic mean concentration of 15 mg/m3 will be used here as
an estimate of the uncertainty in this LOAEL with the under-
standing that this estimate is likely inaccurate. The purpose here is
to illustrate the Bayesian combination of PODs. The value of the
SEM is 2.68 mg/m3 and was estimated with a simulation, similar to
a parametric bootstrap.1 Hence, the uncertainty in this duration-
adjusted LOAEL of 15 ± 2.68 mg/m3 can be represented by a log-
normal distribution with parameters m ¼ 2.692 and s ¼ 0.177
(Limpert et al., 2001).
Echeverria et al. (1995) provide the arithmetic mean and
arithmetic standard deviation equal to 23.2 ± 17.7 ppm in air as the
concentration to which 18 workers were exposed in dry cleaning
shops using a wet-transfer process. They collected PCE measure-
ments in breath and air in the breathing zone of 17 dry cleaners in
Detroit. These concentrations are equivalent to 156 ± 120 mg/m3.
The duration-adjusted values are 56 ± 43 mg/m3. This group is the
moderate exposure group in Table 3 of Echeverria et al. (1995) and
the one chosen by EPA in the PCE Toxicological Review in Table 5-1
as representing a LOAEL (USEPA, 2012b). Using the same simulation
method, the standard error of the mean (SEM) was estimated to be
10.36 mg/m3. Hence, the mean exposure is 56 mg/m3 and the un-
certainty as the SEM is 10.36 mg/m3. Based on these values, the
uncertainty in the LOAEL from Echeverria et al. (1995) can be rep-
resented as a log-normal distributionwith m ¼ 4.009 and s¼ 0.183,
with the same caveats about the inherent uncertainty from un-
known ranges of exposure and sensitivity.
NRC (2014) suggests variance weighting to combine PODs from
different sources and gives several examples. In the following
example, the distribution from Cavalleri et al. (1994) is considered
the prior distribution and that from Echeverria et al. (1995) is
considered as new data to update the prior. This example calcula-
tion is very similar to that on page 123 of NRC (2014). The variance-
weighted POD would be calculated as:
s2prior
s2prior þ s2new
mnew þ
s2new
s2prior þ s2new
mprior ¼
0:17732
0:17732 þ 0:18342$4:009þ
0:18342
0:17732 þ 0:18342$2:692 ¼ 3:328
(13a)
Combining the values from the two studies would give a POD of
28 mg/m3. The standard deviation in natural log space of the log-
normal distribution representing uncertainty in the combined
POD would be:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ 
1
s2prior
þ 1
s2new
!1vuut ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
0:17732
þ 1
0:18342
1s
¼ 0:1274
(13b)1 The simulation was implemented by selecting 35 values at random from a log-
normal distribution with an arithmetic mean of 15 mg/m3 and an arithmetic
standard deviation of 16 mg/m3 and calculating the arithmetic mean of these
selected values. This process was repeated 10,000 times and the standard deviation
of the collection of 10,000 simulated means was assumed to represent the standard
error of the mean.3.5. Example 5ddetermining the percentile of the distribution of
overall uncertainty for RfD development
In the four examples above, we have chosen the lower 95th
percentile (i.e. the 5th percentile) of the log-normal distribution
representing the individual UFs or the POD. Here, examples of
different choices are explored for both the value of the UF and the
percentile this value represents reﬂect the state of knowledge or
conﬁdence regarding the various sources of uncertainty. The
choices of UF value and the percentile dictate the value of the
standard deviation (Table 1). We expect guidance to emerge
regarding these choices as more experience with Bayesian appli-
cation of UFs is gained. Here, we provide three illustrations of
altering the value of UFs using the example of phenol.
The ﬁrst method involves choosing a different value for an un-
certainty factor. The 95th percentile would be maintained and
these two choices would dictate the value of s. Hence, for the
phenol example, the value of 2 rather than 3 would be chosen as
UF-D indicating a lower level of concern for the completeness of the
toxicity database; EPA indicated that this database UF was used
because immunologic and hematologic endpoints were not
examined in the rodent developmental studies, and thus, any
values derived from consideration of developmental and repro-
ductive studies may not be applicable because of this missing
endpoint. From Table 1, the value of the standard deviation is 0.421
corresponding to a UF value of 2 at the 95th percentile is used, and
the RfD for phenol would be calculated as:
lnð157Þ  1:645*
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:3182 þ 1:42 þ 1:42 þ 0:4212
p
¼ 1:686
(14a)
RfD ¼ e1:686 ¼ 5:4y5 mg=kg=d (14b)
Because of the need to round to one signiﬁcant ﬁgure (USEPA,
1989), the choice of a UF of 2 versus 3 makes no difference in the
ﬁnal value of the RfD.
The second method would be the selection of a different
percentile of UF-D to be represented by the numerical value of 3.
This choice also dictates the value of s. One can assume this study
deﬁciency was of less concern than the complete lack of any
developmental study and thus warranted the assumption that the
UF value of 3 actually occurred at the 99.5% one-sided conﬁdence
limit and would dictate s equal to 0.427. Hence, the RfD for phenol
would be calculated as:
lnð157Þ  1:645*
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:3182 þ 1:42 þ 1:42 þ 0:4272
p
¼ 1:667
(15a)
RfD ¼ e1:667 ¼ 5:3y5 mg=kg=d (15b)
Although numerically slightly higher than the unrounded value
from example 1, rounding to one signiﬁcant ﬁgure would give the
same ﬁnal value of the RfD. If UF-D were of greater concern, one
could also set this value at a lower not a higher percentile. Hence, if
one chose UF-D ¼ 3 to occur at the 90th percentile, this choice
would dictate a value of s equal to 0.857 and the resulting
unrounded RfD would be 4.3 mg/kg/d, which would round to 4 mg/
kg/d.
The third method uses Monte Carlo simulation and generally
requires specialized software. Here, we used 100,000 Monte Carlo
iterations to obtain percentile values of the overall standard devi-
ation corresponding to the overall uncertainty in the phenol RfD.
Here, we use the notation F as representing the underlying normal
distribution of the logarithmic values representing the various
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ural log of the overall standard deviation.
ln UFoverallð Þ ¼ FPOD þ FUFA þ FUFH þ FUFD
where
FPOD ¼ N 0:0; 0:318ð Þ;
FUFA ¼ FUFH ¼ N 0:0; 1:4ð Þ;
FUFD ¼ N 0:0; 0:668ð Þ;
(16a)
RfD ¼ expðlnð157Þ þ p05ðlnðUFoverallÞÞÞ (16b)
The value of the 5th percentile of the ln (UFoverall) used in Eq.
(16b) would correspond to the 95th percentile of uncertainty.
Values below the 50th percentile of this combined distribution
would be negative because no adjustments were made (i.e. m ¼ 0
for all UFs) and the value of this chosen percentile would be added
to the POD (or the absolute value subtracted from the POD). From
the Monte Carlo results, the values of the RfD corresponding to the
1st, 2.5th, 5th and 10th percentiles were 1.1, 2.5, 4.9 and 10.4 mg/
kg/d respectively. At the 5th percentile, the resulting rounded RfD
of 5 mg/kg/d is the same as that obtained with Eq. (3) and would
not be expected to be different from the original phenol estimate
except by sampling error. Hence, considering the traditional sour-
ces of uncertainty in the RfD, one could be 95% conﬁdent that an
RfD value below 5 mg/kg/d would be protective of all humans,
including potentially sensitive subpopulations; also, one could be
90% conﬁdent that an RfD value below 10 mg/kg/d would also be
protective.
In the ﬁrst example in this section, the choice of different UF
value, which prescribed the value of s at a given percentile, was
illustrated. In the second example, the chosen UF value was placed
at a higher percentile, reﬂecting a lower contribution of UF-D to the
overall uncertainty. This choice also prescribed the value of s for
the distribution of UF-D. The third example used a relatively simple
Monte Carlo simulation to obtain a range of UF values and corre-
sponding RfDs. Several NRC reviews and EPA guidance documents
point out that providing policy makers with risk estimates span-
ning a range of overall uncertainty may serve as a more useful
decision tool than a single point estimate of risk (USEPA,1992; NRC,
1994; USEPA, 2001; NRC, 2009). As experience is gained with the
Bayesian methods for UFs, some wisdom and resulting guidelines
for the choices of percentile values or ranges of uncertainty will
likely emerge.4. Results
Twenty-four chemicals were examined in this exercise. The re-
sults and detailed calculations are provided in the Supplementary
Content. Table 3 provides an overview of the results; in this table,
three values of each RfD or RfC from each of three approaches are
showndthe IRIS value, the value obtained by using a single log-
normal distribution for the composite UF (Eq. (1a)), and the value
obtainedwhen one treats the individual UFs as separate log-normal
distributions (Eq. (1b)). Because each assessment has its own
characteristics, there are differences in the application of the three
approaches. For example, in the cases of perchlorethylene and
chloroprene, PODs were combined by variance weighting as illus-
trated earlier and described on page 123 of NRC (2014).
All RfD/RfC values listed under the heading “Individual. UFs” in
Table 3, save that for ammonia, increased when compared with the
value found on IRIS. The reason is that the reﬁned Bayesian method
(Eq. (1b)) assumes the uncertainty is along a distribution, which is a
convolution of individual distributions representing the uncer-
tainty of the POD and each individual UF, respectively. In compar-
ison, the Composite UF approach (Eq. (1a) and with the heading“Composite UF” in Table 3) assumes the total uncertainty is char-
acterized by a single distribution of which the variance is deter-
mined by the composite UF, with generally a default-based value of
up to 3000, in combinationwith the uncertainty in the POD; hence,
in the Composite UF approach, only two sources of uncertainty are
considered within the Bayesian frameworkdthat in the POD and
that in the composite UF. Considering the value of the combined
variance as a measure of uncertainty, the range of uncertainty
under the Composite UF approach is greater than that under Indi-
vidual UF approach as discussed earlier.
This point about multiple sources of uncertainty is well illus-
trated by the RfC for ammoniadthis value was based on a NOAEL to
which a single UF accounting for human variability (UF-H) was
applied. Because the POD was a NOAEL and not a BMD, the un-
certainty in the POD could not be determined and only a single
component of variance was present. In all other assessments
considered here, two or more variance components were present
(Table 3; Fig. 2A).
In comparison to the IRIS derivations, the RfV values developed
with the Individual UF method increased with both the value of the
composite UF and the number of UFs used. When 2, 3 and 4 UFs
were used, the geometric means of the fold change increase over
the IRIS value were approximately 2.6, 8.6 and 26 respectively
among the chemicals considered in this exercise. Fig. 2A shows
graphically how the fold change values increase with the value of
composite UF. For composite UF values of 30, 100, 300, 1000 and
3000, the geometric mean fold increases were 3.2, 3.7,13, 20 and 34
respectively. In contrast, the geometric mean fold change when
using the composite UF did not show an increase, or any pattern,
with the value of the composite UF.
Fig. 2B shows that when individual UFs are used in a Bayesian
framework, the fold change increase of this reﬁnement of the NRC
methodology over the IRIS value gets smaller with increased so-
phistication of the assessment; assessments that used PBPKmodels
had generally the smallest fold change values, and assessments that
relied solely on UFs had the greatest fold change values. With this
method reﬁnement, when UFs only are used, the geometric mean
fold change is 22; when dosimetric adjustment factors are used, the
geometric mean fold change is 8.6; and, when PBPK models are
used, the geometric mean fold change is 3.2. When the composite
UF was used in lieu of individual UFs, the fold change over the IRIS
did not show a decrease with the level of sophistication in the
assessment.
5. Discussion
Science and Decisions: Advancing Risk Assessment suggests that
the choice of percentiles of uncertainty/adjustment/extrapolation
factors is the purview of the risk practitioner (NRC, 2009). For hu-
man variability, this choice represents the population level of
protection from the adverse effect of a particular magnitude.
However, with default UFs applied by dividing them into the POD,
the percentile of protection is completely obscured. NRC (2009)
devoted an entire chapter to default values and recommended
that EPA enhance the science basis of default values. Such
enhancement is seen in the Bayesian approach suggested in NRC
(2014). Although the approach is based on default values for UFs,
additional ﬂexibility and transparency is inherent in the choice of
the percentile represented by the default value. In time, default
distributions for uncertainty/adjustment/extrapolation factors
based on data can be developed and used (e.g., WHO-IPCS, 2014).
5.1. POD and UFs as log-normal distributions
Toxicity results from the interaction of a xenobiotic chemical
Table 3
Assessment Details and Results of the Use of Bayesian Methods Compared to the IRIS Approaches (page 1 of 2). The column “Composite UFs” shows the result of using Eq. (1a) for the overall s and the column “Individual UFs”
shows the result of using Eq. (1b) for the overall s. For all UFs, the value of m was assumed to be zero. The RfD or RfC is in the same units as the POD.
Substance and
date assessed
Type of
toxicity value
POD Status Uncertainty factors Dosimetric adjustment
called “method of analysis” in IRIS
Resulting RfD/RfC (mg/kg/d or mg/m3) Fold change individual
UFs vs. IRIS method
IRIS
method
Composite
UFs (Eq. (1a))
Individual
UFs (Eq. (1b))
Ammoniaa (Aug. 2013) RfC NOAEL ¼ 3.1 mg/m3 Draft UFH ¼ 10 None 0.3 NA NA 1
N-butanol (Sept. 2011) RfD BMD10 ¼ 56.5 mg/kg/d Draft UFA ¼ 10; UFH ¼ 10; UFD ¼ 3; None 0.09 0.2 2 22
BMDL10 ¼ 26.1 mg/kg/d
RfC NOAEL-HEC ¼ 59 mg/m3 Draft UFA ¼ 3; UFH ¼ 10; UFD ¼ 3;
UFS ¼ 10;
PBPK Model 0.06 0.06 0.2 3.3
Vanadium Pentoxide
(Sept. 2011)
RfD NOAEL ¼ 10.5 mg/kg/d Draft UFA ¼ 3; UFH ¼ 10; UFS ¼ 10;
UFD ¼ 10;
DAF ¼ 0.24 9.E-04 9E-04 8.E-03 8.9
RfC BMC10 ¼ 0.0045 mg/m3 Draft UFA ¼ 3; UFH ¼ 10; UFD ¼ 10; DAF ¼ 0.26 1.E-05 1E-05 1.E-04 10
BMCL10 ¼ 0.0031 mg/m3
Methanol (Sept. 2013) RfC BMD1SD ¼ 1730 mg-hr/L Final UFA ¼ 3; UFH ¼ 10; UFD ¼ 3; PBPK 20 30 50 2.5
BMDL1SD ¼ 858 mg-hr/L
1,4-Dioxane
(Sept. 2013)
RfD NOAEL - 9.6 mg/kg-d Final UFA ¼ 10; UFH ¼ 10; UFD ¼ 3 None 0.03 0.03 0.3 10
RfC NOAEL ¼ 32.2 mg/m3 Final UFA ¼ 3; UFH ¼ 10; UFL ¼ 10; UFD ¼ 3 Allometric
DAF ¼ 1
0.03 0.03 1 33
Biphenyl (Aug. 2013) RfD BMD10 ¼ 92 mg/kg/d Final UFA ¼ 10; UFH ¼ 10 Allometric
DAF ¼ 0.24
0.5 0.7 2 4
BMDL10 ¼ 58 mg/kg/d
TCDD (Feb. 2012) RfD LOAEL ¼ 0.02 ng/kg/d Final UFH ¼ 3; UFL ¼ 10 PBPK model 7.E-10 7E-10 2.E-09 2.9
Perchlorethyleneb
(Feb. 2012)
RfC LOAELs ¼ 56 & 15 mg/m3 Final UFH ¼ 10; UFL ¼ 10; UFD ¼ 10 None 0.04 0.03 0.5 12.5
Phenol (Sept. 2002) RfD BMD1SD ¼ 157 mg/kg/d Final UFA ¼ 10; UFH ¼ 10; UFD ¼ 3 None 0.3 0.5 5 17
BMDL1SD ¼ 93 mg/kg/d
Dichloromethane
(Nov. 2011)
RfD 1st %ile internal HED Final UFA ¼ 3; UFH ¼ 3; UFD ¼ 3 PBPK þ allometric scaling 0.006 0.02 0.05 8.3
BMD10 ¼ 18.4 mg/L liver/d
BMDL10 ¼ 13.0 mg/L liver/d
RfC 1st %ile internal HED Final UFA ¼ 3; UFH ¼ 3; UFD ¼ 3 PBPK; allometric scaling 0.6 0.7 1.5 2.5
BMD10 ¼ 532 mg/L liver/d
BMDL10 ¼ 130 mg/L liver/d
Substance and date
assessed
Type of
toxicity factor
POD Status Uncertainty factors Dosimetric adjustment
called “Method of Analysis” in IRIS
Resulting RfD/RfC (mg/kg/d or mg/m3) Fold change individual
UFs vs. IRIS method
IRIS
method
Composite
UFs (Eq. (1a))
Individual
UFs (Eq. (1b))
Trichloroacetic Acid
(Sept. 2011)
RfD BMD10 ¼ 40.7 mg/kg/d Final UFA ¼ 10; UFH ¼ 10; UFD ¼ 10 None 0.02 0.04 0.7 35
BMDL10 ¼ 17.9 mg/kg/d
Hexachloroethane
(Sept. 2011)
RfD BMD10 ¼ 1.34 mg/kg/d Final UFA ¼ 10; UFH ¼ 10; UFS ¼ 3; UFD ¼ 3 None 7.E-04 0.001 0.03 43
BMDL10 ¼ 0.728 mg/kg/d
RfC NOAEL ¼ 83 mg/m3 Final UFA¼ 3; UFH¼ 10; UFS¼ 10; UFD¼ 10 None 0.03 0.03 0.3 10
Acrylamide
(March 2010)
RfD BMD10 ¼ 0.58 mg/kg/d Final UFA-TD ¼ 3; UFH ¼ 10 Hb adduct equivalence and PK
conversion
0.002 0.004 0.003 1.5
BMDL05 ¼ 0.27 mg/kg/d
Chloropreneb
(Sept. 2010)
RfC BMDLs ¼ 2.3, 2.1, 2.1
mg/m3
Final UFA ¼ 3; UFH ¼ 10; UFD ¼ 3 DAF ¼ RDDR ¼ 1 0.02 0.03 0.08 4
cis-1,2-
Dichloroethylene
(Sept. 2010)
RfD BMD10 ¼ 19.8 mg/kg/d Final UFA¼ 10; UFH¼ 10; UFS¼ 10; UFD¼ 3 None 0.002 0.006 0.3 150
BMDL10 ¼ 5.1 mg/kg/d
trans-1,2-
Dichloroethylene
(Sept. 2010)
RfD BMD1SD ¼ 126 mg/kg/d Final UFA¼ 10; UFH¼ 10; UFS¼ 10; UFD¼ 3 None 0.02 0.04 2 100
BMDL1SD ¼ 65 mg/kg/d
Pentachlorophenol
(Sept. 2010)
RfD LOAEL ¼ 1.5 mg/kg/d Final UFA ¼ 10; UFD ¼ 10; UFL ¼ 3 None 0.005 0.005 0.05 10
1,1,2,2-
Tetrachloroethane
(Sept. 2010)
RfD BMD1SD ¼ 22 mg/kg/d Final UFA ¼ 10; UFH ¼ 10; UFS ¼ 3; UFD ¼ 3 None 0.02 0.02 0.6 30
BMDL1SD ¼ 15 mg/kg/d
Carbon tetrachloride
(March 2010)
RfC BMD10 HEC ¼ 18.1 mg/m3 Final UFA ¼ 3; UFH ¼ 10; UFD ¼ 3 PBPK model 0.1 0.2 0.5 5
BMDL10 HEC ¼ 14.3 mg/m3
a Bayesian methods were not used in the case of the ammonia RfC because a single source of uncertaintydhuman variabilitydwas considered in the development of the ammonia RfC. The value using either Bayesian method
is the same as that in IRIS.
b Variance-weighted POD was used for NRC and reﬁned methods.
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Fig. 2. Separation by Method of Analysis and Value of the Composite UF. A. Dot plot of fold change increases of the reﬁned method over the IRIS value of RfD/RfCs by the value of the
composite UF. B. Dot plot of fold change increases over the IRiS value by dosimetric adjustment/method of analysis. The horizontal lines show the geometric mean.
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the principles of thermodynamics, dose is most appropriately
expressed as a logarithm (Waddell, 2008). The history of toxicology
is often divided into three eras: Pre-classical from the time of Par-
acelsus to the start of the 20th century, Classical from 1900 until
1965, and Current, from 1965 until the present (Waddell, 2010). In
The Mode of Action of Drugs on Cells, Clark (1933) points out that the
“intensity of maximum action and the duration will vary as the
logarithm of dosage, whilst the amount of action will vary as some
multiple of the logarithm of the dosage.” In the Current era, the use
of the logarithm of dosage has been recommended to achieve ho-
mogeneity of variance (Igarashi and Sekido, 1996; Igarashi et al.,
1996), for calculation of the plasma concentration of propofol
when used as a human anesthetic (Bruhn et al., 2003) and for ex-
amination of the effects of antinociceptive drugs in mice (Luszczki
and Czuczwar, 2008; Luszczki, 2010). Rozman et al. (1996) have
even suggested a dose scale using the number of molecules of an
agent, which necessitates the use of a logarithmic scale because of
the very large numbers, around 1019.
In the Current Era of toxicology, the linearized multistage model
emerged as a purely statistical approach to dose-response and risk
assessment (Waddell, 2010). Regulatory agencies have accepted the
linear no-threshold hypothesis as the basis of the biological effects
of ionizing radiation and chemical exposure (Calabrese, 2009,
2015); this acceptance has spurred considerable and continuing
diversity of opinion among toxicologists regarding the best quan-
titative representation of dose (Crump and Clewell, 2003; Waddell,
2003; Bogen, 2014; Simon, 2014).
NRC (2014) takes a welcome long view regarding the current
state of risk assessment and acknowledges the value of different
types of data, such as animal testing, human epidemiologic data,
and high throughput in vitro test results in developing toxicity
values as well as suggesting that Bayesian methods provide a more
systematic and ﬂexible approach for quantitative consideration of
uncertainties. The consideration of these various data types will
necessitate the use of biological knowledge and mode of action in
risk assessment. The increased use of adverse outcome pathways
(AOPs) to understand and contextualize data from various sources
reﬂects this growing necessity (Villeneuve et al., 2014a,b; Becker
et al., 2015; Patlewicz et al., 2015). Perhaps even more impor-
tantly, Bayesian methods place value on the knowledge and beliefs
of the risk assessor.
However, despite the historical use of the log-normal distribu-
tion, what remains unknown is whether uncertainty or variation inthe estimator of a POD at a designated effect level is also log-
normally distributed. Log-normal distributions have the advan-
tage of reproducibility, i.e. the ratio involving multiple factors re-
mains a log-normal distribution, enabling simple computation as
illustrated in this paper. The extent to which a lognormal distri-
bution is satisfactory is case-speciﬁc. Our choice of using log-
normal distribution is to further illustrate the approach of the
NRC (2014). The true form of the distribution of the BMD remains
unknown, and further research in this area is needed. Hence,
similar to the NRC and others in the history of RfV development, we
acknowledge this imprecision and also chose to represent both the
POD and the UFs with log-normal distributions.
In the case when the distribution of the uncertainties or varia-
tion of POD deviates from a log-normal distribution, modern sta-
tistical tools such as the Markov chain Monte Carlo methods
support the integrative process of combining uncertainties across
multiple areas (Jones et al., 2009; Hennessey et al., 2010; Shao and
Gift, 2013; Wilson et al., 2014). To this end, more experience needs
to be gained and access to appropriate software may be also be
needed. However, using distributions to representing uncertainty
will provide policy makers additional information upon which to
base their decisions and also provide greater transparency
regarding the various sources of uncertainty (NRC, 2007a).
The long history and considerable experimental and conceptual
support for the use of logarithms as themost appropriate expression
of quantitative dose also suggests that the log-normal distribution is
an appropriate way to express uncertainty in dose. Recently, the
relationship between the logarithms of both dose and response is
useful in understanding the shape and steepness of the dose-
response curve (Slob and Setzer, 2014). The mathematical tracta-
bility of this distribution is a highly useful consequence. Other dis-
tributions may be used to express the various types of uncertainty
accounted for in RfD/RfC derivation and Bayesian Monte Carlo
simulation is one means of using other distributions. The use of
Bayesian Markov Chain Monte Carlo methods for PBPKmodeling in
risk assessment is a well-studied and mature technique (Bois et al.,
2010). In addition, such a quantitative framework may help inte-
grate data for use by risk managers (Hill, 1996; Linkov et al., 2009).5.2. The use of distributions to represent UFs
In the early days of using safety factors, a number of individual
components of uncertainty were combined into an overall factor
without quantifying these individual components. When
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developed, their quantiﬁcation was rudimentarydbased only on
the number of human digits, the same as our base ten numbering
system. Considerable effort has been put forth to provide a basis for
quantiﬁcation of UFs (Pieters et al., 1998; Renwick and Lazarus,
1998; Burin and Saunders, 1999; Bruckner, 2000; Haber et al.,
2002; Meek et al., 2002; Pelekis et al., 2003; Pelekis and
Krishnan, 2004; Bokkers and Slob, 2005, 2007; Dorne, 2005;
Price et al., 2008; Hasegawa et al., 2010; Blackburn et al., 2015).
Despite this effort, almost all IRIS assessments use a value of 10 or 3
(√10) for all UFs (Stedeford et al., 2007).
The understanding of traditional UFs is grounded in the indi-
vidual factors and not their combination. Assigning distributions to
the UFs is fraught with difﬁculties in addition to the choice of
distributional parameters. How much should UFs be subdivided?
Both WHO-IPCS (2005) and EPA (2014) split UF-A and UF-H into
toxicokinetic and toxicodynamic components. Thus far, the value of
these individual components is almost always three (3). We would
thus interpret this choice as a log-normal distribution with m ¼ 0
and s ¼ 0.668 (Table 1). But this question remains unanswered:
does this the value of three as the 95th percentile or the use of this
log-normal distribution provide sufﬁcient coverage?
In keeping with the concept of UF distributions that provide
both an adjustment and a degree of uncertainty, an early paper by
Baird et al. (1996) was prescient regarding the current WHO-IPCS
uncertainty guidance. These authors presented distributions rep-
resenting UF-A, UF-H, UF-S and UF-L based on the available data at
that time, assumptions about species heterogeneity in humans and
test species, and general statistical considerations.
Chiu and Slob (2015) also separate adjustment from uncertainty
and also add variability as a category of uncertainty for UF-H. The
distinction here is between aleatory uncertainty or variability
referring to known population heterogeneity combined with un-
certainty in selection an individual from this population and
epistemic uncertainty referring to lack of knowledge about phe-
nomena (Helton and Burmaster, 1996). Both Chiu and Slob (2015)
and WHO-IPCS (2014) add a dosimetric adjustment based body
size expressed as the ratio of a fractional powers of the body
weights of humans and the test species in addition to UF-A based
on toxicokinetic or toxicodynamic differences. Such dosimetric
adjustments have been used in RfC development for many years
(USEPA, 1994).
WHO-IPCS (2014) also chose to represent UF distributions as
log-normal. This document also presents values for the parameters
of missing distributions based on previously compiled data.
Supplemental Table 1 provides values for the means and standard
deviations of these distributions from WHO-IPCS (2014) and other
sources. Included are distributions for uncertainty in NOAEL values,
UF-S and subacute-to-chronic extrapolation, the portion of UF-A
remaining after body size adjustment, UF-H-TK, and UF-H-TD.
The WHO-IPCS guidance also provides a discussion of the inap-
propriateness of using UF-L to estimate a NOAEL and that the dis-
tribution of the LOAEL-to-NOAEL ratio reﬂects predominantly the
dose spacing used in the toxicological studies. WHO-IPCS (2014)
also does not mention the use of UF-D for database deﬁciencies.
5.3. Are the UF distributions independent?
The other issue is that of dependencies between the distribu-
tions representing the various UFs. As discussed, generic distribu-
tions have been developed to represent the UFs (Price et al., 1997;
Swartout et al., 1998). Others have used data on a relatively large
number of chemicals to determine distributions for UF-S, UF-L, UF-
H (Renwick and Lazarus, 1998; Burin and Saunders, 1999; Bokkers
and Slob, 2005, 2007; Dorne, 2005; Dourson et al., 2013; WHO-IPCS, 2014). WHO-IPCS (2014) suggests that the distributions
used for UF-S, UF-A and UF-H are considered independent; while
independence of these distributions seems likely, this statement is
without empirical support at present.
In the future, the combination of extant in vivo data along with
in vitro data from human cell lines considered in a systems biology
perspective may be the most fruitful approach for understanding
potential dependencies between intra- and interspecies tox-
icokinetic and toxicodynamic variabilitydalthough this remains to
be seen (Zeise et al., 2013; Abdo et al., 2015a, 2015b). The number of
dependencies in this areawould be limited by the complexity of the
biology and understanding of mode of action.
Considering UF-S and UF-L, one can envision potential de-
pendencies that may arise from budget constraints on experi-
mental designdtoo few doses to ﬁnd a NOAEL and a LOAEL or
insufﬁcient resources to perform a chronic studydor other non-
scientiﬁc factors.
Until such time that an array of chemical dose-response data of
sufﬁcient quantity is assembled to be able to assess any de-
pendencies between the various UFs, the assumption of indepen-
dence made in WHO-IPCS (2014) seems appropriate.
5.4. Additional considerations for Bayesian methods of UF
application
5.4.1. Magnitude of effect and population incidence
An exposure to an individual will result in a toxicological effect
of a particular magnitude; over a population, the same exposure
will result in variable effect magnitudes across individuals. Hence, if
one speciﬁes a particular magnitude of effect, a ﬁxed exposure to a
populationwill result in an incidence of the toxicological effect of a
given magnitude because individuals differ in their susceptibility
(Chiu and Slob, 2015; WHO-IPCS, 2014). If one considers both effect
magnitude and population incidence, the application of an
extrapolation/adjustment/uncertainty factor becomes more difﬁ-
cultdboth the effect size and the population coverage of the factor
need to be deﬁned.
In current EPA practice, the selection of the effect magnitude is
tacit, implicit in the choice of critical effect. Hence, the RfV, as
deﬁned by EPA and considered here, represents a dose of a chem-
ical associatedwith an effect of an unspeciﬁedmagnitude for which
the incidence in the human population is believed to be zero, i.e.
100% coverage (WHO-IPCS, 2014).
5.4.2. At what stage of the assessment should PBPK models be
applied?
If an assessment involves a PBPKmodel for toxicokinetic species
extrapolation, the stage at which the model is applied becomes
another choice. Fig. 1 indicates that UF-A-TD is applied to the ani-
mal dose metric before using the human PBPK model to convert
this dose metric into an external dose or human-equivalent con-
centration. The choice of the point in the RfV process to use the
PBPK model makes a difference, and below, we use the methanol
RfC discussed earlier as an example.
Using the human PBPKmodel for methanol (Eq. (10)) as the ﬁrst
step to obtain the BMD and BMDL as HEC values provides 1101 ppm
and 780 ppm. The uncertainty in this POD and its application along
with all the UFs would be:
lnð1101Þ  1:645*
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:2092 þ 0:6682 þ 1:42 þ 0:668
p
¼ 4:20
RfC ¼ e4:20 ¼ 67 ppm ¼ 101 mg=m3
(17)
In contrast, using Eq. (6) after applying the uncertainty in the
POD and all the UFs to the animal dose metric would give:
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ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:4262 þ 0:6682 þ 1:42 þ 0:6682
p
¼ 4:59
Adjusted Human Dose Metric ¼ e4:59 ¼ 98:5 mg hr=L
(18)
The human PBPK model equation (Eq. (10)) would then be used
to convert this result to a HEC of 145 ppm or 190.7 mg/m3 or
rounded to 200 mg/m3 that would become the RfC.
Application of the human PBPK model as indicated in Fig. 1
produced a RfC value 2.5-fold higher than the IRIS value. The two
values immediately above are ﬁve-fold and ten-fold respectively
higher than EPA’s derivation. For comparison the OSHA PEL for
methanol has a value of 260 mg/m3 and is based on a non-
quantitative consideration of acute effects in workers (NIOSH,
1976).
Hence, guidance on the best practices for the use of PBPK
models together with Bayes methods for applying uncertainty
factors is needed. Each of the ﬁve UFs has a different speciﬁcity for a
stage or aspect of the assessment. The speciﬁcity of UF application
provides the conceptual basis of Fig. 1. However, this is an area that
clearly needs more examples and additional thought.5.5. Assessment decisions and best practices
At this point in time, we can offer two recommendations to risk
assessors.
 Use Bayesian Methods for UF/CSAF/DDEF application as illus-
trated in this paper consistent with the suggestions of NRC
(2014). One major advantage is the ability to update RfD/RfC
values rapidly as new information becomes available; and
 Use care in determining the default values or percentiles for the
various UFs. As noted, our expectation is that data-derived dis-
tributions characterized by both means and standard deviations
will emerge to replace the default distributions in Table 1 and in
NRC (2014).
 When using Bayesian methods in a RfV derivation that includes
a PBPK model, the stage at which the UFs are applied will likely
make a potentially large difference in the resulting value of the
RfV and more experience in this area is needed.
As time goes by and greater familiarity with these Bayesian
methods grows, additional ideas for best practices will very likely
emerge. Nonetheless, the methods described here can be imple-
mented immediately in the IRIS program and used for the devel-
opment of RfD/RfC values henceforth. The imprecision in the
extrapolations used to develop RfVs indicate that expressing an RfV
as a distribution or as a selected percentile of distribution will
improve the clarity and transparency of these necessary and
important regulatory criteria.Funding and acknowledgements
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